# Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synendos-therapeutics-starts-phase-2-trial-in-generalized-anxiety-disorder/ > **Published:** 2026-05-20T10:07:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:54:42-04:00 > **Clinical Summary:** SERI endocannabinoid reuptake inhibitors represent a novel approach to anxiety by enhancing the body's own cannabinoid signaling without exogenous cannabis. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AnxietyMental HealthNeurologyResearchSafetyIndustrySleep Why This Matters Clinicians treating generalized anxiety disorder need to monitor this SERI development as a potential alternative to traditional anxiolytics, particularly for patients who experience adverse effects from benzodiazepines or SSRIs. If Phase 2 data demonstrates efficacy and tolerability, this endocannabinoid-modulating approach could expand the therapeutic toolkit for [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) and inform discussions about mechanism-based treatment selection. Understanding emerging cannabinoid therapies helps clinicians stay current on novel pharmacological options that may eventually offer improved safety profiles or efficacy in treatment-resistant populations. Clinical Summary Synendos Therapeutics has initiated a Phase 2 clinical trial investigating a novel class of [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulators called selective endocannabinoid receptor agonists (SERIs) for the treatment of generalized anxiety disorder. This development represents a significant advancement in cannabis-related therapeutics, as SERIs are designed to modulate endocannabinoid signaling with greater selectivity and precision than whole-plant cannabis or broad-spectrum cannabinoid products, potentially reducing off-target effects and improving tolerability. If successful, this trial could provide clinicians with a pharmacologically characterized, standardized treatment option for [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/), addressing current limitations of existing anxiolytics and potentially offering an alternative for patients who have inadequate response to or intolerance of conventional agents. The mechanism of action through [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) restoration aligns with emerging neurobiology of anxiety but will require Phase 2 data to establish clinical efficacy and safety profiles before any practice implications can be determined. Clinicians should monitor the results of this trial as a potential future addition to the [anxiety treatment](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/) armamentarium, though currently no changes to clinical practice are warranted pending completion of controlled efficacy studies. Dr. Caplan’s Take “What’s clinically significant here is that we’re finally moving beyond plant-derived cannabinoids to rationally designed molecules that target specific endocannabinoid pathways, which means we could potentially offer anxiety patients efficacy without the psychoactive side effects that limit current [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). If this SERI class proves out in Phase 2, we’re looking at a fundamentally different therapeutic tool than what we’ve had available.” Clinical Perspective This Phase 2 trial of a selective endocannabinoid reuptake inhibitor (SERI) for generalized anxiety disorder represents a potentially important mechanistic advance, as targeting the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) offers a theoretically distinct approach from conventional anxiolytics like SSRIs and benzodiazepines. However, clinicians should recognize that translating promising preclinical endocannabinoid biology into clinical efficacy has proven challenging in previous trials, and the long development timeline for cannabis-derived therapies reflects genuine uncertainty about tolerability, safety profiles, and potential cognitive or psychiatric side effects that may not emerge until larger studies. The trial design, patient selection criteria, and comparator arms will be crucial for determining whether SERIs offer genuine advantages over existing treatments or merely add another option with uncertain benefit-risk characteristics. Until Phase 2 and Phase 3 data demonstrate clear clinical superiority, effic 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/stress-management/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Synendos%20Therapeutics%20Starts%20Phase%202%20Trial%20in%20Generalized%20Anxiety%20Disorder%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55810)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55810)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Synendos%20Therapeutics%20Starts%20Phase%202%20Trial%20in%20Generalized%20Anxiety%20Disorder%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D55810)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://markets.businessinsider.com/news/stocks/synendos-therapeutics-starts-phase-2-trial-in-generalized-anxiety-disorder-1036177961](https://markets.businessinsider.com/news/stocks/synendos-therapeutics-starts-phase-2-trial-in-generalized-anxiety-disorder-1036177961) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) CED Clinic Blog[Fear of recurrence, secondary cancers, and health problems in long-term survivors of childhood cancer: Findings from a Canadian cohort.](https://cedclinic.com/fear-of-recurrence-secondary-cancers-and-health-problems-in-long-term-survi/) CED Clinic Blog[Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical cannabis patients across 45 days.](https://cedclinic.com/associations-of-cannabis-use-other-substances-and-lifestyle-choices-on-anxi/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).